Cathy Yeung > Latham & Watkins LLP > Hong Kong, Hong Kong > Lawyer Profile
Latham & Watkins LLP Offices
18TH FLOOR, ONE EXCHANGE SQUARE
8 CONNAUGHT PLACE
CENTRAL HONG KONG
Hong Kong
- Firm Profile
- Go to...
Cathy Yeung
Position
Cathy Yeung serves as Chair of Latham & Watkins’ Greater China Practice and formerly served as Global Vice Chair of the firm‘s Capital Markets and Public Company Representation Practices. She advises on a full range of PRC-related corporate transactions.
Ms. Yeung draws on more than two decades of experience to advise leading investment banks and Chinese companies on the following types of corporate transactions:
-
- Capital markets, including initial public offerings and secondary offerings
- Mergers and acquisitions, including public M&A
- Privatizations
- Private equity
She also advises listed companies across a full range of industries on regulatory and compliance as well as corporate governance matters.
Ms. Yeung, a native mandarin speaker, was born and raised in China, and received her legal education in China and Hong Kong, so brings a strong understanding of Chinese culture and business practice to her work. She regularly leads global teams of market leading-colleagues from across the firm to efficiently and seamlessly address Chinese clients’ needs.
She served as the company secretary of Bank of China from 2008-2015.
Ms. Yeung speaks at seminars regarding the rules governing the securities listings on the Stock Exchange of Hong Kong and corporate governance.
Lawyer Rankings
Hong Kong > Capital markets (equity)
(Leading individuals)Acting on its own as well as frequently in collaboration with lawyers on the mainland, Latham & Watkins LLP handles a significant volume of IPOs and follow on offerings for underwriters and issuers, both in Hong Kong and the US. Although the firm’s versatile practice is comfortable handing transactions across a wide range of industry sectors, under the guidance of Cathy Yeung it has, in recent years, been particularly active handling issuances in the TMT, life sciences and new economy sectors. As well as transactional work the team has been involved in a consultative role on the development of the SPAC regime and pre-revenue biotech companies, and has continued to assist regulators in applying the nascent listing regimes. Benjamin Su is central to much of the firm’s work in the TMT space and has developed excellent ties with both Chinese issuers and international underwriters.